VP11-2021: Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study

T. André, A Falcone, Y. Shparyk, F. V. Moiseenko, E. Polo Marques, T. Csoszi, A. Campos Bragagnoli, Gabor Liposits, E. Chmielowska, P. Aubel, L. Martín-Fernández, R. Fougeray, N. Causse-Amellal, Mark P Saunders

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

OriginalsprogEngelsk
ArtikelnummerVP11-2021
TidsskriftAnnals of Oncology
Vol/bind33
Udgave nummer2
Sider (fra-til)229-230
ISSN0923-7534
DOI
StatusUdgivet - feb. 2022
Udgivet eksterntJa
BegivenhedESMO Immuno-Oncology Congress 2021 -
Varighed: 8. dec. 202111. dec. 2021

Konference

KonferenceESMO Immuno-Oncology Congress 2021
Periode08/12/202111/12/2021

Citationsformater